Anaemia Management in Dialysis
On this page
Direct answer
The anaemia of dialysis patients is chiefly erythropoietin deficiency compounded by iron loss into the dialyser, repeated blood sampling and uraemic inflammation, and it is managed to a target haemoglobin of roughly 10-11.5 g/dL — per KDIGO guidance, erythropoiesis-stimulating agents are considered when Hb falls toward 9-10 g/dL and are never used to push levels above 11.5, since higher targets increased stroke and thrombotic events in trials. Iron is the co-passenger: intravenous iron sucrose (a common Indian regimen is 100 mg per session for ten sessions, then maintenance) aims to keep ferritin above about 200 ng/mL and transferrin saturation above 20-30 per cent in haemodialysis patients. A patient who needs ever more ESA is not a dosing problem but a diagnostic one — iron deficiency, infection, blood loss, hyperparathyroidism and aluminium toxicity all masquerade as hyporesponsiveness.
What you must remember
- Target band: Hb 10-11.5 g/dL; do not initiate ESA above 10, do not chase normal haemoglobins — the CREATE, CHOIR and TREAT trials all penalised higher targets.
- Iron goals in HD: ferritin above about 200 ng/mL (with a working ceiling near 500-800 beyond which yield falls) and TSAT above 20-30 per cent before and during ESA therapy.
- ESA menu: short-acting erythropoietin (about 50-150 units/kg per week in divided doses — commonly 2000-4000 units IV thrice weekly at initiation), darbepoetin weekly to fortnightly, and monthly CERA-like agents; titrate monthly, not weekly.
- IV iron sucrose regimen: 100 mg per dialysis session × 10 sessions (1000 mg total) then individualised maintenance; oral iron is largely ineffective in HD because of absorption and phosphate interactions.
- Hyporesponsiveness checklist (in order): iron deficiency, overt or occult blood loss, infection or inflammation (including silent access infection), inadequate dialysis, severe hyperparathyroidism, B12/folate deficiency, haemolysis, aluminium toxicity, malignancy and hypothyroidism.
- Transfusion caution: reserve for symptomatic anaemia or Hb generally below about 7 g/dL; transfusions sensitise potential transplant candidates (HLA antibodies) and carry infection risk.
- Practical technologist roles: administering IV iron during the session, watching for ESA-related hypertension and thrombosis of access, and ensuring the monthly Hb, ferritin and TSAT actually get drawn.
Working up ESA hyporesponsiveness
A woman has climbed from 4000 to 12,000 units of erythropoietin thrice weekly while her haemoglobin slides from 10.6 to 8.9. Resist the reflex to escalate further — the dose escalation itself is the diagnostic clue. Step one, iron studies: ferritin 84, TSAT 14 per cent — she is iron-deficient despite a year of ESA, from diagnostic blood draws and dialyser losses outrunning intake; a repletion course of iron sucrose 100 mg × 10 sessions is started. Step two, interrogate the calendar: her Kt/V last quarter was 0.95 (sessions repeatedly shortened for transport), and underdialysis blunts erythropoiesis independently — the prescription is restored to full hours. Step three, the occult sources: a positive stool occult blood sends her for gastroenterology review; the parathyroid hormone returns at fourteen times the upper limit, flagged for the MBD pathway.
Six weeks later, on iron plus adequate dialysis alone, her haemoglobin is 10.1 on half the previous dose — the lesson being that ESA dose is a dependent variable, and the workup ladder (iron, blood loss, infection, dialysis dose, PTH) is the examinable content.
How the exam frames it
Numbers dominate: the target band (10-11.5 g/dL), the ferritin and TSAT thresholds (above 200 ng/mL, above 20-30 per cent), and the iron sucrose regimen (100 mg × 10). Conceptual MCQs ask why ESA targets are capped — higher Hb targets increased cardiovascular events in trials — and why transfusions are minimised in transplant candidates (HLA sensitisation). The viva favourite is the failing ESA: an ordered differential with iron deficiency first and hyperparathyroidism, infection and underdialysis in the list, delivered as a workup rather than a guess. Indian framing adds the practical reality: ESAs are a major out-of-pocket cost, so monthly monitoring and iron optimisation are the levers that keep doses — and bills — low.
Frequently asked questions
What haemoglobin target is aimed for in dialysis patients on ESA therapy?
Roughly 10-11.5 g/dL; ESAs are started when Hb trends toward 9-10 g/dL and doses are not escalated to normalise haemoglobin because of cardiovascular risk.
What iron parameters should be maintained during ESA therapy?
Ferritin above about 200 ng/mL and transferrin saturation above 20-30 per cent in haemodialysis patients, achieved with intravenous iron sucrose courses.
List the causes of ESA hyporesponsiveness.
Iron deficiency, blood loss, infection or inflammation, inadequate dialysis, severe hyperparathyroidism, B12 or folate deficiency, haemolysis and aluminium toxicity.
Why are blood transfusions minimised in dialysis patients awaiting transplant?
Transfusions can induce HLA antibody sensitisation, reducing the chance of a compatible donor kidney, besides carrying infection risks.
What is a standard intravenous iron regimen in Indian dialysis units?
Iron sucrose 100 mg per session for ten sessions (1000 mg total) followed by individualised maintenance dosing guided by ferritin and TSAT.